Novo Nordisk
Use attributes for filter ! | |
Web site | www.novonordisk.com |
---|---|
Stock price | NOVO-B |
Disclaimer | |
Headquarters | Bagsværd |
Denmark | |
Ceo | Lars Fruergaard Jørgensen |
Revenue | 111. 7 billion DKK (2017) |
Founders | Hans Christian Hagedorn |
Subsidiaries | Ziylo Ltd |
Aldaph SpA | |
Calibrium, LLC | |
Did you know | Novo Nordisk is the world's 10th-largest independent biotech company by market cap ($111. 9 B). |
Address | Etiler Mahallesi, Nispetiye Cd. Akmerkez İş Kuleleri E3 Blok, 34335 Beşiktaş/İstanbul |
Phone | (0212) 385 40 40 |
Date of Reg. | |
Date of Upd. | |
ID | 713149 |
About Novo Nordisk
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, with production facilities in eight countries, and affiliates or offices in 75 countries.
The online black market cashing in on weight loss jab hype
... Drugs manufacturer Novo Nordisk is the only company approved to sell and market semaglutide, branded as Ozempic and Wegovy, in the UK, but it is now battling against knock-off online sales...
Wegovy: Weight-loss drug firm becomes Europe's most valuable
... Shares rose after the Danish pharmaceutical giant, Novo Nordisk, launched the popular drug in the UK...
NHS gets limited stock of Wegovy weight-loss jab
... The Danish maker of Wegovy, Novo Nordisk, said it would continue to restrict global supplies as it works to ramp up manufacturing...
Weight-loss apps to offer NHS help to obese
... The company which makes it, Novo Nordisk, recently said it was restricting the number of doses it is supplying to different countries to make sure patients have the correct all-round care and support in place when they start taking the drug...
Weight-loss drug reduces stroke and heart risk
... But the company behind the drug, Novo Nordisk, says it has a clear medical benefit, as well as being able to help people lose weight...
Weight-loss jabs investigated for suicide risk
... Manufacturer Novo Nordisk is working with the EMA and says patient safety is a top priority...
Weight loss drug semaglutide approved for NHS use
... Ozempic face Pharmaceutical company Novo Nordisk, which makes both Ozempic and Wegovy, says the products should only be used as recommended by a doctor...
Hollywood weight loss jab to be sold by Boots chemist
... Boots will soon be offering an online service once the drug, made by Novo Nordisk, becomes available in the UK...
Wegovy: Weight-loss drug firm becomes Europe's most valuable
By Mariko OiBusiness reporter
The maker of weight-loss drug, Wegovy, has become Europe's most valuable firm dethroning the French luxury conglomerate LVMH.
Shares rose after the Danish pharmaceutical giant, Novo Nordisk , launched the popular drug in the UK.
At the close of trading on Monday, The Firm had a stock market valuation of $428bn (£339bn).
and also on the private market.
Wegovy is an obesity treatment that is taken once a week which tricks people into thinking that they are already full, so they end up eating less and losing weight.
Famous personalities such as, which has captivated Hollywood and The Public more widely since it was approved by regulators in the US in 2021.
Wegovy and Ozempic - a diabetes treatment with similar Effects - have been described as " miracle" drugs.
But experts warn the jabs are not a quick fix nor a substitute for a healthy diet and exercise.
In trials, users often put weight back on after stopping treatment.
There has been a global shortage of the jabs so only limited stock arrived for the UK's National Health System (NHS).
The Company said it would continue to restrict global supplies as it worked to ramp up manufacturing.
In the UK, say patients can only access Wegovy, which contains the drug semaglutide, if they are significantly overweight and have weight-related health problems.
According to the Organisation for Economic Co-operation and Development (OECD), nearly one in three adults are obese in the UK which is the highest level in Europe.
Last month, a New Trial showed Wegovy has also been proven to.
While the findings still have to be fully reviewed, experts agreed the results were potentially significant.
Related TopicsSource of news: bbc.com